Vincent Dochez

Dr. Vincent Dochez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
VDVincent Dochez
Vincent Dochez
HCHélène Caillon
Hélène Caillon
EVEdouard Vaucel
Edouard Vaucel
JDJérôme Dimet
Jérôme Dimet
NWNorbert Winer
Norbert Winer
GDGuillaume Ducarme
Guillaume Ducarme
Ovarian cancer is the 5th leading cause of death for women with cancer worldwide. In more than 70% of cases, it is only diagnosed at an advanced stage. Our study aims to give an update on the biological markers for diagnosing ovarian cancer, specifically HE4, CA 125, RMI and ROMA algorithms. Serum CA125 assay has low sensitivity in the early stages and can be increased in certain conditions such as menstruation or endometriosis. The level of HE4 is overexpressed in ovarian tumors. Its specificity is 94% and its level is not affected by endometriosis cysts. The combined measures of CA125 and HE4 have proved to be highly efficient with an area under the curve (AUC) of up to 0.96. Furthermore, this combined measure of CA125 can correct the variations in HE4 which are due to smoking or contraception combining estrogen plus progestin. While the specificity of RMI sometimes reaches 92%, the rather low AUC of 0.86 does not make it the best diagnostic tool. The specificity of ROMA is lower than HE4 (84% compared to 94%). To date, the most efficient biological diagnostic tool to diagnose ovarian cancer is the combination of CA125 and HE4.

1 April 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
MDManon Degez
Manon Degez
HCHélène Caillon
Hélène Caillon
ACAnne Chauviré-Drouard
Anne Chauviré-Drouard
MLMaxime Leroy
Maxime Leroy
DLDavid Lair
David Lair
VDVincent Dochez
Vincent Dochez

25 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VDVincent Dochez
Vincent Dochez
MRMélanie Randet
Mélanie Randet
CRCéline Renaudeau
Céline Renaudeau
JDJérôme Dimet
Jérôme Dimet
ATAurélie LE THUAUT
Aurélie LE THUAUT
GDGuillaume Ducarme
Guillaume Ducarme
Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of malignancy index (RMI) and the risk of ovarian malignancy index (ROMA) to predict ovarian cancer in women with PBOT. Methods: It is a prospective, observational, multicentre, laboratory-based study including women with PBOT in four hospitals from 11 May 2015 through 12 May 2016. Preoperative CA125 and HE4 plasma levels were measured for all women. The primary endpoint was the specificity of CA125 and HE4 for diagnosing ovarian cancer. The main secondary endpoints were specificity and likelihood ratio of RMI, ROMA and tumours markers. Results: Two hundred and fifty patients were initially enrolled and 221 patients were finally analysed, including 209 benign ovarian tumours (94.6%) and 12 malignant ovarian tumours (5.4%). The malignant group had significantly higher mean values of HE4, CA125, RMI and ROMA compared to the benign group (p < 0.001). Specificity was significantly higher using a combination of HE4 and CA125 (99.5%) compared to either HE4 or CA125 alone (90.4% and 91.4%, respectively, p < 0.001). Moreover, the positive likelihood ratio for combination HE4 and CA125 was significantly higher (104.5; 95% CI 13.6–800.0) compared to HE4 alone (5.81; 95% CI 2.83–11.90) or CA125 alone (6.97; 95% CI 3.91–12.41). Conclusions: The combination of HE4 and CA125 represents the best tool to predict the risk of ovarian cancer in patients with a PBOT.

20 October 2019 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
VDVincent Dochez
Vincent Dochez
JEJulie Esbelin
Julie Esbelin
EMEmilie Misbert
Emilie Misbert
CAChloé Arthuis
Chloé Arthuis
ADAnne Drouard
Anne Drouard
NWNorbert Winer
Norbert Winer

1 September 2021 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
AGAlizé Gilbert
Alizé Gilbert
TTThibault Thubert
Thibault Thubert
VDVincent Dochez
Vincent Dochez
ARAnne-Sophie Riteau
Anne-Sophie Riteau
MDMathilde Ducloyer
Mathilde Ducloyer
DADAVID Arthur
DAVID Arthur

14 November 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
ASAnaïs Sevestre
Anaïs Sevestre
RSRobin Souron
Robin Souron
TDThibault Deschamps
Thibault Deschamps
ASAurélie Sarcher
Aurélie Sarcher
TTThibault Thubert
Thibault Thubert
VDVincent Dochez
Vincent Dochez
Introduction: Laparoscopy has become a fundamental aspect of surgery, presenting new challenges such as fatigue, encompassing both muscular and cognitive components. Given its potential to affect surgical precision and create difficulties for the surgeon, it is crucial to study the mechanisms of fatigue for patient safety and the well-being of surgeons. This study aims to demonstrate the influence of general fatigue on surgeons’ performance, incorporating assessments of movement quality through balance, kinematics, and muscle activation, as well as perceived workload. Additionally, the study seeks to evaluate how surgeons’ experience may affect fatigue outcomes.Methods and analysis: A controlled cross-over laboratory trial involving 29 residents and surgeons from the obstetrics and gynecology department of Nantes University Hospital is underway. Recruitment started in March 2023 and ended in September 2023. Participants with varying levels of experience perform two one-hour sessions of training box exercises, one in the morning (control condition) and the other at the end of a workday. The primary outcome is a composite score derived from the time to complete the Suturing and Knot Tying Training and Testing (SUTT) exercise, along with the number and quality of stitches. Secondary outcomes include perceived fatigue, discomfort, physical strain, muscle tension, mental workload, muscle activation (measured by surface electromyography), balance (measured using a force platform), and kinematics (measured using motion capture).Ethics and dissemination: The study received ethical approval from the local ethics committee CERNI in December 2022 (n°13,122,022). Results will be presented in international conferences, submitted to peer-reviewed journals, and serve as a feasibility study for subsequent publications.